Immune globulin
- PDF / 169,624 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 39 Downloads / 169 Views
1
Immune globulin Eczematous rash: case report A 59-year-old man developed eczematous rash following treatment with immune globulin for common variable immunodeficiency (CVID). The man, who had CVID, was receiving treatment with IV infusion of immune globulin [IVIg; dosage not stated] since 2011. Subsequently, he presented with an erythematous, macular, pruritic dermatitis that had developed in the right antecubital fossa 3–4 hours after receiving IV immune globulin infusion. The dermatitis relapsed and remitted for several days and also started to involve the left antecubital fossa. The man did not respond to unspecified antihistamines and showed mild improvement with unspecified steroids. His IV immune globulin treatment was switched to SC immune globulin. In the subsequent 4 months, the eczematous rash did not recur. Author comment: "Eczematous skin reactions are an uncommon but a reported adverse effect of [IV immune globulin]" "To the best of our knowledge, this is the first reported case managed by changing [IV immune globulin] to a subcutaneous formulation." Humble B, et al. FIRST REPORTED MANAGEMENT OF A RARE ADVERSE REACTION TO IVIG BY TRANSITION TO SUBCUTANEOUS PRODUCT. Annals of Allergy, Asthma and Immunology 123 (Suppl.): S83, No. 5, Nov 2019. Available from: URL: https://www.annallergy.org/issues [abstract] 803431858 USA
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
Data Loading...
